data + articles · 4 listed
newest 2018spec sheet11 rows
Oleoylethanolamide (OEA) is a naturally occurring lipid molecule that acts as a satiety signal in the body. It is the ethanolamide of oleic acid, a member of the fatty acid ethanolamide family that also includes the endocannabinoid anandamide, though OEA works through different pathways. Produced in the small intestine in response to eating fat, it reduces appetite and food intake mainly by activating the nuclear receptor PPAR-alpha. It has been studied extensively in relation to feeding, body weight, and obesity, and is sold as a dietary supplement.
- Reduces appetite and sweet cravings
- Supports modest weight and waist reduction
- Encourages fat burning through PPAR-alpha
- Lowers markers of inflammation and oxidative stress
- May improve insulin sensitivity markers
- Pairs well with a calorie-aware diet
Overview
Oleoylethanolamide is an endogenous lipid, specifically the amide formed between oleic acid and ethanolamine, placing it in the family of bioactive fatty acid ethanolamides [1]. It is closely related in structure to the endocannabinoid anandamide, of which it can be regarded as a monounsaturated analogue, but unlike anandamide it does not act on cannabinoid receptors and instead exerts its effects through separate targets [1]. In pure form it is a white solid.
The compound is manufactured by the body itself, chiefly by the absorptive cells lining the upper small intestine [2]. When dietary fat is digested, the oleic acid it yields is converted within these cells into OEA through a sequence of enzymatic steps, so that the molecule is produced precisely when fat is being absorbed [2][3]. In this way OEA functions as a chemical report on dietary fat intake.
Its best-characterized role is as a peripheral satiety signal [1][2]. Rising OEA in the gut produces a state of fullness marked by longer intervals between meals and reduced feeding frequency rather than an abrupt stop to a single meal [2]. This message is carried from the intestine to the brain along sensory fibers of the vagus nerve, reaching hypothalamic centers that govern appetite, so the signal originates in the gut but acts through the nervous system [2][4].
Research has extended these observations across a wide range of animals, and OEA has been implicated in the control of feeding and body weight in species as varied as mice and pythons [1]. It also promotes the oxidation of fat and enhances energy expenditure, effects tied to its regulation of lipid-handling machinery, and studies note that a sustained high-fat diet can blunt the OEA satiety signal, a disruption proposed to contribute to overweight and obesity [3]. Beyond feeding, laboratory work has explored possible neuroprotective and other effects [4].
OEA acts at more than one molecular target, with the nuclear receptor PPAR-alpha regarded as its primary site of action, alongside reported activity at the receptor GPR119 and the TRPV1 ion channel [1][2]. It is both a naturally occurring signaling lipid and a research compound, and it is marketed as a dietary supplement, typically promoted for appetite control and weight management, although rigorous human clinical evidence remains limited [3].
Mechanism
Oleoylethanolamide produces its main effects by acting as a high-affinity natural of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), a -activated transcription factor that governs many genes involved in fat metabolism [1]. When OEA generated in the intestine binds PPAR-alpha, it switches on programs that increase the oxidation of fatty acids and raise energy expenditure, and it drives the anorexic, or appetite-suppressing, signal for which the molecule is known [1][3].
This satiety effect is not exerted directly on the brain; instead, OEA formed in the gut engages sensory fibers of the vagus nerve, which relay the signal to feeding-control centers in the , with additional neurochemical mediators such as oxytocin implicated in the response [2][4]. Part of the metabolic action involves increased expression of the fatty acid transporter CD36, linking fat sensing in the intestine to the downstream PPAR-alpha response [3]. OEA can also interact with other targets, including the G-protein-coupled receptor GPR119 and the TRPV1 channel, which may contribute to its overall physiology, but activation of PPAR-alpha is considered central to its regulation of feeding and body weight [1][2].
receptor fingerprint
PPAR-alphaAgonist
Appetite regulationSuppressant
Reducer
Safetyrisks and cautions, not medical advice
Oleoylethanolamide (OEA) is an endogenous lipid mediator and has been well tolerated in short-term clinical trials, with mild gastrointestinal disturbance the most frequently reported complaint. Other occasional effects noted in trials include headache, sleep difficulty, and appetite suppression with weight loss, consistent with its satiety-signaling action. Long-term safety data are limited, so its durable risk profile is not established. As a general caution, individuals with liver or kidney conditions or those on other medications should have use supervised, given the possibility of interactions and hypersensitivity.
Subjective profileweighing the evidence above
A sensible, low-risk addition when appetite is the thing getting in the way, since the satiety mechanism is well characterized and the small human trials point the same direction. Effects are modest and the trials are short, so expect a nudge alongside a diet rather than a replacement for one.
Resources
This entry is here for reference.
Research
- 2005first citedRegulation of food intake by oleoylethanolamide.
- 2018most recentOleoylethanolamide: The role of a bioactive lipid amide in modulating eating behaviour.
- 1.Regulation of food intake by oleoylethanolamide.
- 2.A fatty gut feeling.
- 3.Oleoylethanolamide: The role of a bioactive lipid amide in modulating eating behaviour.
- 4.Brain molecules and appetite: the case of oleoylethanolamide.
4 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Is OEA a GLP-1 drug?
No; it is a natural satiety lipid working through PPAR-alpha, though it may nudge gut hormone signaling indirectly.
Will it work without dieting?
Effects are modest; it helps most as a tool alongside a sensible calorie-aware diet, not instead of one.
When should I take it?
Before meals, since its job is to prime the fullness signal before you start eating.
Limitations of the evidence
- Marketed as a dietary supplement, though rigorous human clinical evidence is limited
- Long-term human safety at supplemental intakes has not been well established
Notes and cautions
- A naturally occurring lipid the body makes in the gut after eating fat
- Its central action is to reduce appetite and lengthen the time between meals
- Generally reported as well tolerated in experimental studies, with mild digestive effects possible